



Rizatriptan Formulation

Versio 3.9		Revision Date: 2020/10/10		S Number: 2485-00013	Date of last issue: 2020/03/23 Date of first issue: 2015/12/10					
1. PRODUCT AND COMPANY IDENTIFICATION										
F	Product name		:	Rizatriptan Form	ulation					
r	Manufa	cturer or supplier's d	letai	ils						
(Company		:	Organon & Co.						
ŀ	Address		:	30 Hudson Stree Jersey City, New	et, 33nd floor v Jersey, U.S.A 07302					
٦	Telepho	ne	:	551-430-6000						
E	Emergency telephone number		:	215-631-6999						
E-mail address		:	EHSSTEWARD	@organon.com						
F	Recommended use of the chemical and restrictions on use									

Recommended use	:	Pharmaceutical
	•	i mannaoo anoan

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance Colour Odour	:	powder pink odourless					
Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.							
GHS Classification							
Reproductive toxicity	:	Category 2					
Specific target organ toxicity - repeated exposure	:	Category 2					
GHS label elements							
Hazard pictograms	:						
Signal word	:	Warning					
Hazard statements	:	H361d Suspected of damaging the unborn child. H373 May cause damage to organs through prolonged or re- peated exposure.					
Precautionary statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read					

according to GB/T 16483 and GB/T 17519



Rizatriptan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23	
3.9	2020/10/10	402485-00013	Date of first issue: 2015/12/10	

and understood. P260 Do not breathe dust. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards

Not classified based on available information.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 50 -< 70
Starch	9005-25-8	>= 10 -< 20
Rizatriptan	145202-66-0	>= 3 -< 10

4. FIRST AID MEASURES

General advice	 In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. 	
If inhaled In case of skin contact	 If inhaled, remove to fresh air. Get medical attention. In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. 	y

according to GB/T 16483 and GB/T 17519



Version 3.9	Revision Date: 2020/10/10		Number: 85-00013	Date of last issue: 2020/03/23 Date of first issue: 2015/12/10				
lf swa Most	se of eye contact allowed important symptoms iffects, both acute and ed	T : II : II : G F : S M : S O	in eyes, rinse we bet medical atten swallowed, DO Bet medical atten Rinse mouth thoro Suspected of dam May cause damage exposure. Contact with dust	shoes before reuse. ell with water. tion if irritation develops and persists. NOT induce vomiting.				
	Protection of first-aiders Notes to physician		the skin. Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). Treat symptomatically and supportively.					
5. FIREFI	5. FIREFIGHTING MEASURES							
	Suitable extinguishing media Unsuitable extinguishing media Specific hazards during fire- fighting Hazardous combustion prod- ucts		Vater spray Ncohol-resistant f Carbon dioxide (C Dry chemical None known.					
media Speci			oncentrations, ar	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. pustion products may be a hazard to health.				
			Carbon oxides					
Speci ods	ific extinguishing meth-	c L F s	umstances and t Jse water spray to	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do				
	Special protective equipment for firefighters		n the event of fire	e, wear self-contained breathing apparatus. ective equipment.				
6. ACCIDI	ENTAL RELEASE MEA	SURE	S					
Perso	onal precautions, protec-	: L	Jse personal prot	ective equipment.				

tive equipment and emer- gency procedures	-	Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

according to GB/T 16483 and GB/T 17519



Rizatriptan Formulation

Version	Revision Date: 2020/10/10	SDS Number:	Date of last issue: 2020/03/23
3.9		402485-00013	Date of first issue: 2015/12/10
	ds and materials for ment and cleaning up	tainer for dispo Avoid dispersa with compress Dust deposits es, as these m leased into the Local or nation posal of this m employed in th mine which reg Sections 13 ar	I of dust in the air (i.e., clearing dust surfaces

7. HANDLING AND STORAGE

Handling		
Technical measures		Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation Advice on safe handling		Use only with adequate ventilation. Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Avoidance of contact	:	Oxidizing agents
Storage		
Conditions for safe storage	:	Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.
Materials to avoid	:	Do not store with the following product types: Strong oxidizing agents
Packaging material	:	Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

according to GB/T 16483 and GB/T 17519



Rizatriptan Formulation

sion Revision Date: 2020/10/10		SDS Number: 402485-00013		Date of last issue: 2020/03/23 Date of first issue: 2015/12/10			
Comp	onents	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis		
Cellul	ose	9004-34-6	PC-TWA	10 mg/m3	CN OEL		
			TWA	10 mg/m3	ACGIH		
Starch	1	9005-25-8	TWA	10 mg/m3	ACGIH		
Rizatr		145202-66-		10 µg/m3 (OEB 3)	Internal		
	•		Wipe limit	100 µg/100 cm ²	Internal		
Engineering measures :		design and protect pro Containme are require the compo- tainment de	All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con- tainment devices). Minimize open handling.				
Perso	onal protective equip	ment					
Respiratory protection : Filter type : Eye/face protection : Skin and body protection : Hand protection :		sure asses ommended Particulate Wear safet If the work mists or ae Wear a fac potential fo aerosols. Work unifo Additional	sment demonstra I guidelines, use i s type y glasses with sid environment or a rosols, wear the eshield or other f r direct contact to rm or laboratory o body garments sh	nould be used based u	e the rec- conditions, ere is a nists, or upon the		
		posable su Use approj	task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.				
Ma	aterial	: Chemical-r	esistant gloves				
	emarks ne measures	: If exposure eye flushin ing place. When usin Wash cont The effectin engineering appropriate industrial h	g systems and sa g do not eat, drint aminated clothing ve operation of a g controls, proper degowning and	before re-use. facility should include personal protective e decontamination proc g, medical surveillance	review of quipment, edures,		

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

: powder

according to GB/T 16483 and GB/T 17519




Vers 3.9	sion	Revision Date: 2020/10/10		S Number: 485-00013	Date of last issue: 2020/03/23 Date of first issue: 2015/12/10
	Colour		:	pink	
	Odour		:	odourless	
	Odour ⁻	Threshold	:	No data available	9
	рН		:	No data available)
	Melting	point/freezing point	:	No data available	
	Initial b range	oiling point and boiling	:	No data available	
	Flash p	oint	:	Not applicable	
	Evapor	ation rate	:	No data available)
	Flamma	ability (solid, gas)	:	May form explosi dling or other me	ve dust-air mixture during processing, han- ans.
	Flamma	ability (liquids)	:	No data available	9
		explosion limit / Upper bility limit	:	No data available)
		explosion limit / Lower bility limit	:	No data available	
	Vapour	pressure	:	No data available)
	Relative	e vapour density	:	No data available	9
	Density	,	:	No data available)
	Solubili Wat	ty(ies) er solubility	:	No data available	
		n coefficient: n-	:	No data available	
	octanol Auto-ig	/water nition temperature	:	No data available)
	Decom	position temperature	:	No data available)
	Viscosi Visc	ty osity, kinematic	:	No data available	
	Explosi	ve properties	:	Not explosive	
		ng properties lar weight	:	The substance o No data available	r mixture is not classified as oxidizing.
		U ···			

according to GB/T 16483 and GB/T 17519



/ersion 3.9	Revision Date: 2020/10/10		S Number: 2485-00013	Date of last issue: 2020/03/23 Date of first issue: 2015/12/10		
Par	ticle size	:	No data available			
IO. STA	BILITY AND REACTIVITY	,				
Che	activity emical stability sibility of hazardous reac- s	:	Stable under norr May form explosiv dling or other mea	ve dust-air mixture during processing, han-		
Inco Haz	nditions to avoid ompatible materials cardous decomposition ducts	:	 Heat, flames and sparks. Avoid dust formation. Oxidizing agents No hazardous decomposition products are known. 			
1. TOX	ICOLOGICAL INFORMAT		l			
Exp	osure routes	:	Inhalation Skin contact Ingestion Eye contact			
	Ite toxicity		a fa sua a tha a			
	classified based on availa duct:	ble	information.			
	te oral toxicity	:	Acute toxicity estin Method: Calculatio	nate: > 5,000 mg/kg on method		
<u>Cor</u>	nponents:					
	lulose: ite oral toxicity	:	LD50 (Rat): > 5,00	00 mg/kg		
Acu	te inhalation toxicity	:	LC50 (Rat): > 5.8 Exposure time: 4 h Test atmosphere:	ו ו		
Acu	te dermal toxicity	:	LD50 (Rabbit): > 2	2,000 mg/kg		
Sta	rch:					
Acu	te oral toxicity	:	LD50 (Rat): > 5,00	00 mg/kg		
Acu	te dermal toxicity	:	LD50 (Rabbit): > 2	2,000 mg/kg		
	atriptan: ite oral toxicity	:	LD50 (Rat): 2,227 LD50 (Mouse): 70			





ersion)	Revision Date: 2020/10/10	SDS Numb 402485-000						
Skin	corrosion/irritation							
Not c	lassified based on ava	ilable informati	on.					
<u>Com</u>	ponents:							
Rizat	riptan:							
Speci Resu		: Rabbit : No skin	irritation					
Serio	Serious eye damage/eye irritation							
Not c	Not classified based on available information.							
<u>Com</u>	ponents:							
Starc	h:							
Speci		: Rabbit						
Resu	It	: No eye	rritation					
Rizat	riptan:							
Speci	ies	: Bovine	cornea					
Rema	arks	: Modera	e eye irritation					
Resp	iratory or skin sensi	tisation						
-	sensitisation lassified based on ava	ilable informati	on.					
	iratory sensitisation							
-	lassified based on ava	ilable informati	on.					
<u>Com</u>	ponents:							
Starc	:h:							
Test		: Maximis	ation Test					
	sure routes	: Skin co						
Speci Resu		: Guinea : negative						
		5						
Rizat	riptan:							
Test			ation Test					
Expo: Speci	sure routes	: Dermal : Guinea	oig					
	ssment		t cause skin sensitisation.					
Resu		: negative						
Germ	cell mutagenicity							
	lassified based on ava	ilable informati	on.					
Com	ponents:							
Cellu	lose:							
	toxicity in vitro	: Test Ty	be: Bacterial reverse mutation assay (AMES))				
			8 / 15					
			0710					

according to GB/T 16483 and GB/T 17519



Rizatriptan Formulation

ersion Ə	Revision Date: 2020/10/10	SDS Number: 402485-00013	Date of last issue: 2020/03/23 Date of first issue: 2015/12/10
		Result: nega	ative
		Test Type: I Result: nega	n vitro mammalian cell gene mutation test ative
Genotoxicity in vivo		cytogenetic Species: Mo	Route: Ingestion
Starc	h:		
Geno	toxicity in vitro	: Test Type: E Result: nega	Bacterial reverse mutation assay (AMES) ative
Rizat	riptan:		
Geno	toxicity in vitro	: Test Type: E Result: nega	Bacterial reverse mutation assay (AMES) ative
		Test Type: / Result: nega	Alkaline elution assay ative
		Test Type: I Result: nega	n vitro mammalian cell gene mutation test ative
		Test Type: (Result: nega	Chromosome aberration test in vitro ative
Geno	toxicity in vivo	: Test Type: N cytogenetic Species: Mo Application Result: nega	ouse Route: Oral
	nogenicity assified based on av	ailable information	
	oonents:		
Cellu Speci Applic	lose: es cation Route sure time	: Rat : Ingestion : 72 weeks : negative	
Rizat	riptan:		
	cation Route sure time EL	: Mouse : Oral : 100 weeks : 125 mg/kg b : negative	oody weight

according to GB/T 16483 and GB/T 17519



Versio 3.9	on	Revision Date: 2020/10/10	-	9S Number: 2485-00013	Date of last issue: 2020/03/23 Date of first issue: 2015/12/10			
A E N	Species Application Route Exposure time NOAEL Result		 Rat Oral 106 weeks 106 mg/kg body weight negative 					
S	Suspec	luctive toxicity ted of damaging the u	nboi	m child.				
		onents:						
	Cellulo Effects	se: on fertility	:	Test Type: One-ge Species: Rat Application Route Result: negative	eneration reproduction toxicity study			
	Effects ment	on foetal develop-	:	Test Type: Fertility Species: Rat Application Route: Result: negative	/early embryonic development			
F	Rizatrip	otan:						
	-	on fertility	:	Species: Rat, fem Application Route Fertility: LOAEL: 1 Symptoms: altered	Oral 00 mg/kg body weight d estrus cycles on fertility and early embryonic develop-			
				Species: Rat, male Application Route Fertility: NOAEL: 2	Oral 250 mg/kg body weight on fertility and early embryonic develop-			
	Effects nent	on foetal develop-	:	Species: Rat Application Route Developmental To	o-foetal development Oral xicity: LOAEL: 10 mg/kg body weight enic effects, Embryo-foetal toxicity			
				Species: Rabbit Application Route Developmental To Result: No teratog	o-foetal development Oral xicity: LOAEL: 100 mg/kg body weight enic effects, Embryo-foetal toxicity ects were seen only at maternally toxic dos-			





rsion	Revision Date: 2020/10/10	SDS Number:Date of last issue: 2020/03/23402485-00013Date of first issue: 2015/12/10					
Repro sessn	oductive toxicity - As- nent	: Some evidence of adverse effects on development, based on animal experiments.					
	- single exposure assified based on avai	able information.					
<u>Comp</u>	oonents:						
Rizatriptan:							
	ssment	: May cause drowsiness or dizziness.					
	- repeated exposure						
May c	ause damage to orgar	s through prolonged or repeated exposure.					
<u>Comp</u>	oonents:						
Rizat	riptan:						
	t Organs ssment	 Cardio-vascular system Causes damage to organs through prolonged or repeat exposure. 	ed				
Repe	ated dose toxicity						
<u>Comp</u>	oonents:						
Cellu	lose:						
Speci		: Rat					
NOAE	L cation Route	: >= 9,000 mg/kg : Ingestion					
	sure time	: 90 Days					
Starc	h:						
Speci		: Rat					
NOAE Applic	L cation Route	: >= 2,000 mg/kg : Skin contact					
	sure time	: 28 Days					
Metho		: OECD Test Guideline 410					
Rizat	riptan:						
Speci		: Rat					
LOAE	L cation Route	: 1 mg/kg : Oral					
	sure time	: 14 Weeks					
Symp		: Dilatation of the pupil, Increased pulse rate, Redness					
Speci		: Dog					
LOAE		: 0.05 mg/kg					
	cation Route sure time	: Intravenous : 2 Weeks					
Symp		Dilatation of the pupil, Increased pulse rate, Redness					
Speci	65	: Dog					

according to GB/T 16483 and GB/T 17519



Vers 3.9	sion	Revision Date: 2020/10/10		0S Number: 2485-00013	Date of last issue: 2020/03/23 Date of first issue: 2015/12/10				
	LOAEL Application Route Exposure time Symptoms			0.2 mg/kg Oral 1 yr Dilatation of the pupil					
	-	tion toxicity ssified based on availa	ble	le information.					
	Experie	ence with human exp	osu	sure					
	Compo	onents:							
	Rizatri	ptan:							
	Ingestio	on	:		ardio-vascular system nia, Fatigue, Pain, Dizziness, Weakness,				
12.	ECOLO	GICAL INFORMATION	1						
	Footox	riaitu							
	Ecotox	-							
		onents:							
	Cellulo Toxicity	/ to fish	:	Exposure time: 48	pes (Japanese medaka)): > 100 mg/l 3 h on data from similar materials				
	Rizatri	ptan:							
		/ to fish	:	LC50 (Pimephales Exposure time: 96	s promelas (fathead minnow)): > 1,000 mg/l 5 h				
		v to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48	agna (Water flea)): 1,000 mg/l 3 h				
	Toxicity plants	✓ to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD Te					
				NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te					
	Toxicity icity)	/ to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 32 Method: OECD Te					
		/ to daphnia and other invertebrates (Chron- ity)	:	NOEC (Daphnia r Exposure time: 21 Method: OECD Te					


according to GB/T 16483 and GB/T 17519



Rizatriptan Formulation

Vers 3.9	sion	Revision Date: 2020/10/10		0S Number: 2485-00013	Date of last issue: 2020/03/23 Date of first issue: 2015/12/10
	Toxicity to microorganisms		:	EC50: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD To	h ration inhibition
				NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209	
	Persis	tence and degradabil	lity		
	Compo	onents:			
	Cellulo				
	Biodeg	radability	:	Result: Readily bi	odegradable.
	Rizatri	ptan:			
		Iradability	:	Result: Not readily Biodegradation: 4 Exposure time: 13 Method: OECD To	50 % 3 d
	Bioaco	cumulative potential			
	Compo	onents:			
	Rizatri Partitio octano	n coefficient: n-	:	log Pow: -0.649	
	Mobilit	ty in soil			
	Compo	onents:			
	Rizatri	ptan:			
		ution among environ- compartments	:	log Koc: 3.83 Method: OECD Te	est Guideline 106
	Other	adverse effects			
	No data	a available			
13.	DISPOS	SAL CONSIDERATION	NS		
	Dispos	sal methods			
	Waste	from residues ninated packaging	:		ordance with local regulations. should be taken to an approved waste han- cling or disposal.

dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.





Rizatriptan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
3.9	2020/10/10	402485-00013	Date of first issue: 2015/12/10

14. TRANSPORT INFORMATION

International Regulations

UNRTDG Not regulated as a dangerous good

IATA-DGR Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

GB 6944/12268 Not regulated as a dangerous good

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

National regulatory information Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Further information Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Date format	:	yyyy/mm/dd
Full text of other abbreviation	ons	
ACGIH CN OEL	:	USA. ACGIH Threshold Limit Values (TLV) Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.
ACGIH / TWA CN OEL / PC-TWA	:	8-hour, time-weighted average Permissible concentration - time weighted average

according to GB/T 16483 and GB/T 17519



Rizatriptan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
3.9	2020/10/10	402485-00013	Date of first issue: 2015/12/10

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN